These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 29152077)

  • 21. Comparative study of the PD-L1 expression and CD8+ tumor-infiltrating lymphocyte between surgically resected and matched re-biopsy specimens in recurrent non-small cell lung cancer.
    Shimizu K; Okita R; Saisho S; Maeda A; Nojima Y; Nakata M
    Ther Clin Risk Manag; 2019; 15():605-612. PubMed ID: 31118648
    [No Abstract]   [Full Text] [Related]  

  • 22. An Immunohistochemical Analysis of PD-L1 Protein Expression in Surgically Resected Small Cell Lung Cancer Using Different Antibodies and Criteria.
    Takada K; Toyokawa G; Okamoto T; Akamine T; Takamori S; Katsura M; Fujishita T; Shoji F; Oda Y; Maehara Y
    Anticancer Res; 2016 Jul; 36(7):3409-12. PubMed ID: 27354600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conformance Assessment of PD-L1 Expression Between Primary Tumour and Nodal Metastases in Non-Small-Cell Lung Cancer.
    Xu H; Chen X; Lin D; Zhang J; Li C; Zhang D; Zhang X
    Onco Targets Ther; 2019; 12():11541-11547. PubMed ID: 31920342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Consistency Analysis of Programmed Death-Ligand 1 Expression between Primary and Metastatic Non-Small Cell Lung Cancer: A Retrospective Study.
    Luo L; Luo X; Chen W; Liang C; Yao S; Huang W; Liu C; Ge Y; Lin X; Li Z
    J Cancer; 2020; 11(4):974-982. PubMed ID: 31949500
    [No Abstract]   [Full Text] [Related]  

  • 25. Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy.
    Pinato DJ; Shiner RJ; White SD; Black JR; Trivedi P; Stebbing J; Sharma R; Mauri FA
    Oncoimmunology; 2016; 5(9):e1213934. PubMed ID: 27757309
    [No Abstract]   [Full Text] [Related]  

  • 26. PD-L1 Expression in Squamous-cell Carcinoma and Adenocarcinoma of the Lung.
    Janzic U; Kern I; Janzic A; Cavka L; Cufer T
    Radiol Oncol; 2017 Sep; 51(3):357-362. PubMed ID: 28959173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system.
    Schats KA; Van Vré EA; De Schepper S; Boeckx C; Schrijvers DM; Waelput W; Fransen E; Vanden Bempt I; Neyns B; De Meester I; Kockx MM
    Histopathology; 2017 Jan; 70(2):253-263. PubMed ID: 27496355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
    Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH
    Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
    Cooper WA; Tran T; Vilain RE; Madore J; Selinger CI; Kohonen-Corish M; Yip P; Yu B; O'Toole SA; McCaughan BC; Yearley JH; Horvath LG; Kao S; Boyer M; Scolyer RA
    Lung Cancer; 2015 Aug; 89(2):181-8. PubMed ID: 26024796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer.
    Nakamura S; Hayashi K; Imaoka Y; Kitamura Y; Akazawa Y; Tabata K; Groen R; Tsuchiya T; Yamasaki N; Nagayasu T; Fukuoka J
    PLoS One; 2017; 12(10):e0186192. PubMed ID: 29049375
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer.
    Takamori S; Toyokawa G; Okamoto I; Takada K; Kozuma Y; Matsubara T; Haratake N; Akamine T; Katsura M; Mukae N; Shoji F; Okamoto T; Oda Y; Iwaki T; Iihara K; Nakanishi Y; Maehara Y
    Anticancer Res; 2017 Aug; 37(8):4223-4228. PubMed ID: 28739710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequency of discordance in programmed death-ligand 1 (PD-L1) expression between primary tumors and paired distant metastases in advanced cancers: a systematic review and meta-analysis.
    Lee CC; Soon YY; Lum JHY; Tan CL; Tey JCS
    Acta Oncol; 2020 Jun; 59(6):696-704. PubMed ID: 32193962
    [No Abstract]   [Full Text] [Related]  

  • 33. PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer.
    Zhou C; Tang J; Sun H; Zheng X; Li Z; Sun T; Li J; Wang S; Zhou X; Sun H; Cheng Z; Zhang H; Ma H
    Oncotarget; 2017 Aug; 8(35):58457-58468. PubMed ID: 28938570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
    Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
    Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathological Features and Status of Programmed Death Ligand-1 (PD-L1) Expression in Lung Cancer: A Single Centre Study From North India.
    Ganie F; Mehfooz N; Siraj F; Khan UH; Mantoo S; Dhar A; Mir MH; Jan RA; Shah S; Qadri SM
    Cureus; 2023 Feb; 15(2):e35056. PubMed ID: 36942175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-L1 Expression in Muscle-Invasive Urinary Bladder Urothelial Carcinoma According to Basal/Squamous-Like Phenotype.
    Kim B; Lee C; Kim YA; Moon KC
    Front Oncol; 2020; 10():527385. PubMed ID: 33365265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-L1 Status in Refractory Lymphomas.
    Vranic S; Ghosh N; Kimbrough J; Bilalovic N; Bender R; Arguello D; Veloso Y; Dizdarevic A; Gatalica Z
    PLoS One; 2016; 11(11):e0166266. PubMed ID: 27861596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.
    Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
    Eur J Cancer; 2014 May; 50(7):1361-9. PubMed ID: 24548766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association Between PD-L1 Expression and Metabolic Activity on
    Takada K; Toyokawa G; Tagawa T; Kohashi K; Akamine T; Takamori S; Hirai F; Shoji F; Okamoto T; Oda Y; Maehara Y
    Anticancer Res; 2017 Dec; 37(12):7073-7082. PubMed ID: 29187498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Programmed cell death-ligand 1 (PD-L1) expression and fibroblast growth factor receptor 1 (FGFR1) amplification in stage III/IV lung squamous cell carcinoma (SQC).
    Guo Q; Sun Y; Yu S; Bai H; Zhao J; Zhuo M; Wang J
    Thorac Cancer; 2017 Mar; 8(2):73-79. PubMed ID: 28008744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.